138 filings
8-K
MIST
Milestone Pharmaceuticals Inc
8 Apr 24
Data from this large safety-trial also published in The Journal of the American College of Cardiology
4:38pm
8-K
MIST
Milestone Pharmaceuticals Inc
28 Mar 24
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
7:07am
8-K
MIST
Milestone Pharmaceuticals Inc
21 Mar 24
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
7:21am
10-K
2023 FY
MIST
Milestone Pharmaceuticals Inc
Annual report
21 Mar 24
7:01am
8-K
fdxpit n88jw4
4 Mar 24
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
9:00am
424B5
as4wgw
1 Mar 24
Prospectus supplement for primary offering
4:52pm
424B5
ss53fo8 3r3c7m
28 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
8lg2vx oybgz4u
26 Feb 24
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
7:06am
8-K
8934o5xu85v8g 9qjnz
26 Dec 23
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
7:15am
8-K
d1puiti
13 Nov 23
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
7:05am
8-K
q5dtufj6
13 Nov 23
Company Overview CONFIDENTIAL Atrial Fibrillation Program Update November 2023
6:37am
8-K
jkhuir wax
7 Nov 23
Regulation FD Disclosure
9:07am
8-K
dnekq mpr
24 Oct 23
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
4:05pm
8-K
4fmrdfk5xtgd37k v6x
10 Aug 23
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
7:40am
8-K
448l55zrb ks6b8
9 Jun 23
Submission of Matters to a Vote of Security Holders
5:11pm
424B5
cpxr5t7 gqlf5w8c
31 May 23
Prospectus supplement for primary offering
5:19pm